Neurogene (NGNE) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Neurogene (NGNE) over the past year, gaining 223.1% versus a gain of 2.6%. Nuvectis Pharma is the larger company by market cap ($657.1 million vs $530.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | NVCT |
|---|---|---|
| Share price | $26.50 | $20.13 |
| Market cap | $530.30M | $657.12M |
| 1-day change | +2.44% | -0.79% |
| YTD return | +28.64% | +166.62% |
| 1-year return | +2.59% | +223.11% |
| 5-year return | -81.65% | — |
| EPS (TTM) | $-5.04 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $29.28 |
| 52-week low | $15.93 | $5.55 |
| Distance from 52-week high | -39.30% | -31.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +193.89% | +75.86% |
| Average volume | 247.13K | 215.43K |
| Shares outstanding | 20.01M | 32.64M |
| Employees | 131 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed NGNE by 220.5 percentage points over the past year.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
NGNE vs NVCT FAQ
Which is bigger, Neurogene or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $657.12M compared with $530.30M for Neurogene (NGNE).
Which stock has performed better over the past year, NGNE or NVCT?
NVCT returned +223.11% over the past 12 months, compared with +2.59% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.